Immunotherapy for Pediatric Solid Tumors
There have been dramatic responses for some adult cancers by mobilizing the patient’s immune cells to target the tumor cells. Unfortunately, that success in adult oncology has not translated to children with solid tumors. In order to advance the use of immunotherapy for children with solid tumors, we have launched a major effort to model and study the interactions within the tumor microenvironment for pediatric solid tumors. We have developed the largest and most comprehensively characterized collection of orthotopic patient derived xenografts in the world that includes 166 tumors representing 21 different tumor types (www.stjude.org/CSTN/). In addition, we have started to produce iPSCs from those patients that have corresponding xenografts. We are optimizing differentiation protocols for the normal cells in the tumor microenvironment and studying those interactions in organoids ex vivo and in vivo in humanized mice. Our long-term goal is to develop more effective chemoimmunotherapeutic regimens for children with solid tumors. I am seeking a highly motivated postdoctoral fellow to work as part of a multidisciplinary team made up of computational and stem cell biologists, pediatric oncologists, pathologists and basic scientists to use these innovative new models. Training in immunology and/or human stem cell research is preferred.
Michael A. Dyer, Ph.D.
Chair and Member, Developmental Neurobiology Department
Co-leader Developmental Biology and Solid Tumor Program
St. Jude Children’s Research Hospital
St. Jude Children's Research Hospital does not accept unsolicited assistance from search firms for employment opportunities. Please do not call or email. All resumes submitted by search firms to any employee or other representative at St. Jude via email, the internet or in any form and/or method without a valid written search agreement in place and approved by HR will result in no fee being paid in the event the candidate is hired by St. Jude.